BioVie Completes Phase 2 Parkinson's Trial, Topline Data Expected Q3-2026
BIVI sits 25% above its 52-week low of $1.06.
Summary
BioVie Inc. announced the completion of the last patient evaluation visit for its Phase 2 SUNRISE-PD trial evaluating bezisterim in early-stage Parkinson's disease. This operational milestone is significant for the clinical-stage biotech, confirming the trial's progression towards data readout. The company plans to release topline results in Q3-2026, which will be a critical catalyst. This development provides a positive operational update following the recent 10-Q (May 11) that highlighted a critical cash shortage and a 'going concern' warning, making any progress in its core drug development program important. Investors will now focus on the upcoming data release, which will determine the drug's potential and impact the company's future financing prospects.
At the time of this announcement, BIVI was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.9M. The 52-week trading range was $1.06 to $12.10. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.